Compare Tango Therapeutics Inc. (TNGX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.98B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 5.9× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| TNGX | XLY | |
|---|---|---|
Market Cap | $3.75B | $21.98B |
Volume | 9,619,106 | 5,684,050 |
Sector | Health | — |
52-Week High | $32.90 | $124.52 |
52-Week Low | $7.50 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XLY trades at $112.36 with minimal daily movement (+0.07%), showing technical indecision with a bullish overall signal but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% while consumer staples gained 6.6%. Analyst consensus remains unanimously bullish with a 100% buy rating, though recent news highlights persistent underperformance concerns and consumer spending shifts toward value.
The outlook remains mixed with technical indicators suggesting potential resistance near $113 while fundamental exposure to consumer discretionary spending faces inflation pressures. Key risks include continued market underperformance and consumer sensitivity to economic conditions, though potential catalysts exist from holiday retail growth projections and cyclical sector opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
